Rheumatoid Arthritis Clinical Trial
Official title:
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
To stimulate collaborative efforts of federal funding agencies, voluntary health agencies, professional organizations and industry partners to enable creation of a large, sustainable database and repository to better understand the molecular basis of treatment and rapidly accelerate translational research in RA.
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting ~1% of the US
population. Severity of RA varies from mild synovitis to joint destruction with associated
disability and increased mortality. Methotrexate (MTX) is the major drug used to treat RA
and the anchor drug for clinical trials of investigational new drugs (INDs) in RA. Eight
biologic agents are currently FDA-approved for RA. No drug is effective in every patient,
and there is great variability in toxicity and price.
The use of concomitant MTX and biologic agents has dramatically improved the outcomes of RA
treatment in the US. This proposal is based on the premise the next major advance needed in
the treatment of RA is not additional drugs, but rather a dramatic improvement in the
efficiency and cost-effectiveness of the use of drugs for individual patients with RA. One
of the hopes for modern medicine is the realization of "personalized" medicine, which allows
accurate, quick prediction of which drug will be the most efficacious, least toxic, and
least expensive for an individual patient.
One of the major obstacles to identifying clinically useful markers of treatment response in
RA is the lack of cohorts with prospectively collected treatment response data coupled with
biological samples. Because of the importance of this issue and the paucity of funding for
such efforts, multiple efforts to establish single institution (using institutional funds)
or multisite cohorts and repositories (typically dependent on private practitioners and
pharmaceutical company support) are planned. To date, there has been no attempt to harmonize
the efforts of the US academic RA research community to create a public resource.
Recognizing that building de novo cohorts within a short time frame is not feasible, our
current proposal will fill a critical need: establishing an infrastructure of academic
investigators to lay the foundation for future collaborative large-scale registries; and
uniting the efforts of many organizations with the common goal of improving care of RA
patients. This project will facilitate future research that will result in significant,
publicly visible improvements in health care. Identifying predictors of treatment response
in RA will lead to rapid, early institution of optimal drugs rather than a "hit or miss"
sequential approach; reduce adverse events; improve patient compliance; and lead to
substantial reduction in the cost of health care. By unifying the efforts of academic
researchers, we can create unique resources, such as a bank of cryopreserved blood cells to
allow sophisticated immunologic research to dissect molecular signals of successful
treatment of RA.
In order to determine the feasibility of this infrastructure for prospectively collecting
data and samples we will enroll a small number of participants (10/site/year for each of 2
years, for a total of 200 participants).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |